Transdermal fentanyl: Clinical pharmacology

摘要: Abstract The transdermal therapeutic system (TTS) fentanyl has been designed for rate-controlled drug delivery. It provides a convenient regimen the use of previously limited by short duration action and noninvasive parenteral route that is unsuitable oral administration. TTS developed to provide continuous controlled systemic delivery base 72 hr. rectangular, transparent unit composed protective peel strip four functional layers. amount released from, each (25 μg/hr per 10 cm2) proportional surface area. So far, patch sizes are available (10–40 cm2). When applied, depot concentrates in upper skin Fentanyl plasma concentration not measurable until 2 hr after application, it takes 8–16 latency full dinical effects observed. Steady-state serum concentrations obtained several sequential 72-hr applications, these maintained as long applied. Following removal, decline gradually fall about 50% approximately 16 This prolonged apparent elimination half-life occurs because continues be absorbed from skin. Transdermal transport essentially same between chest, abdomen, thigh. skin-permeability constant 0.0125 mL/hr/cm2, much lower than regional blood supply chest-skin Because potential permeability variations among individuals, special rate-controlling membrane additional control release. reduces 50%. Small amounts alcohol used an absorption enhancer. appears valuable tool chronic pain patients requiring opiate treatment but is, due its delay decay times, probably routine management short-lasting acute states.